Evidence map›Paper›PMID 23634241›Full record

ArticleAmerican journal of translational research2013

The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters.

Mette J Nielsen, Anders F Nedergaard, Shu Sun, Sanne S Veidal, Lise Larsen, Qinlong Zheng, Charlotte Suetta, Kim Henriksen, Claus Christiansen, Morten A Karsdal and 1 more

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of translational research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03294850 (Evaluation of Biomarkers to Quantify Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis at Baseline and Following Bariatric Surgery), which is not on this map. Cited by 158 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
158citing papers in PubMed, 2 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03294850 nacompletednot on this mapstarted 2018, after this paper: background citation

Evaluation of Biomarkers to Quantify Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis at Baseline and Following Bariatric Surgery (BARI)

TypeinterventionalSponsorAdventHealth Translational Research InstituteRan2018 to 2020Enrolled14ConditionsNASH - Nonalcoholic Steatohepatitis, NAFLD - Nonalcoholic Fatty Liver DiseaseArmsBariatric surgery, HepQuant SHUNT Dual Cholate Liver Diagnostic Kit
3 · Its place in the literature

Who cites it

158 citing papers in PubMed, 2 syntheses or guidelines pooled it, 214 citations in OpenAlex.

  1. Pooled it
  2. Serum Biomarkers of Renal Fibrosis: A Systematic Review.International journal of molecular sciences · 2022
    Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. LPARespiratory research · 2022
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

98 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Mette J NielsenNordic Bioscience, Fibrosis Biology and Biomarkers Herlev, Denmark.
Anders F Nedergaard
Shu Sun
Sanne S Veidal
Lise Larsen
Qinlong Zheng
Charlotte Suetta
Kim Henriksen
Claus Christiansen
Morten A Karsdal
Diana J Leeming
Nordic Bioscience (Denmark) · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe present study describes the assessment of true formation of type III collagen in different pathologies using a neo-epitope specific competitive Enzyme-linked immunosorbent assay (ELISA) towards the N-terminal propeptide of type III collagen (PRO-C3).

methodsThe monoclonal antibody was raised against the N-protease mediated cleavage site of the N-terminal propeptide of type III collagen and a competitive ELISA was developed using the selected antibody. The assay was evaluated in relation to neo-epitope specificity, technical performance, and as a marker for liver fibrosis and muscle mass using the rat carbon tetrachloride (CCl4) model and a study of immobilization induced muscle loss in humans, respectively.

resultsThe ELISA was neo-epitope specific, technically stable and can be assessed in serum and plasma samples. In the CCl4 liver fibrosis model it was observed that serum PRO-C3 were significantly elevated in rats with liver fibrosis as seen by histology (56% elevated in the highest quartile of total hepatic collagen compared to control rats, p<0.001) and correlated significantly to total hepatic collagen in the diseased rats (r=0.46, p<0.01) and not in control rats, suggesting the pathological origin of the epitope. Human plasma PRO-C3 correlated significantly to muscle mass at baseline (R(2)=0.44, p=0.036).

conclusionThe developed neo-epitope specific serum ELISA for type III procollagen (PRO-C3) reflects true formation as it is specific for the propeptide cleaved off the intact collagen molecule. In a clinical and in a rodent study we showed that this marker was highly related to liver fibrosis and muscle mass.

Indexed as

Biochemical markersformationliver fibrosismuscle massneo-epitopetype III collagen

Identifiers

PMID23634241
PMCPMC3633973
OpenAlexW15077488

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.